P1 À 170 Efficacy of EGFR tyrosine kinase inhibitors for EGFR mutatnt nonsmall cell lung cancer with brain metastases

Niigata Cancer Center Hospital
Background: Central nervous system (CNS) is a common site of metastases of nonsmall cell lung cancer (NSCLC). The prognosis for patients with brain metastases and/ or leptomeningeal carcinomatosis is extremely poor. NSCLC harboring epidermal growth factor receptor (EGFR) mutation generally shows good response to tyrosine kinase inhibitors (TKI). However, data on the efficacy of EGFR-TKI in patients with CNS metastases remain limited. Methods: We retrospectively evaluated clinical outcome and background of EGFR mutant NSCLC patients with CNS metastases who received EGFR-TKI for first line drug therapy between January 2008 and December 2014 in the facilities belong to Niigata lung cancer treatment group. Results: A total of 104 eligible patients were enrolled. The response rate was 62%. The median time to treatment failure was 7.8 months. The median progression free survival (PFS) was 8.4months. The median survival time was 24.0 months. The response rate of CNS was 37%. The median CNS-PFS was 13.2 months. There was no statistical significant difference in TTF, PFS and overall survival (OS) between exon 19 deletion and exon 21 L858R point mutation or between two EGFR-TKIS used; Gefitinib and Erlotinib. Brain radiotherapy prior to EGFR-TKI tended to prolong TTF and PFS, but was not significantly associated with OS. Conclusion: EGFR-TKI showed favorable effect for EGFR mutant NSCLC patients with CNS metastases. We will show further analysis at the meeting. Background: Nivolumab has shown superiority over docetaxel in the 2nd line treatment of both squamous cell and non-squamous cell non-small-cell lung cancer (NSCLC) in two randomized phase 3 studies (CheckMate 017/057). Subject and Method: Fifteen patients with pretreated NSCLC who received nivolumab were retrospectively investigated.
Result: Of 15 patients, 5 were male and 10 were female, and the median age was 73.0 (range, 63 to 82). The numbers of adenocarcinoma (wild type), EGFR-mutant, squamous cell carcinoma (SqCC) were 10, 1, 4, respectively. Three patients were administered as 2nd line, 6 were as 3rd line, and 6 were as 4-6th line treatment. Best overall responses were partial response in 4, stable disease in 8, progressive disease in 2, and not evaluable in 1. Response ratio (RR) was 26.7%, disease control ratio (DCR) was 80.0%, and median progression free survival (PFS) was 56days (range, 13-281). Among 11 patients with adenocarcinoma, RR and DCR were 18.2% and 72.7%, respectively. Among 4 patients with SqCC, RR and DCR were 50.0% and 100%, respectively. While RR and DCR were 33.3% and 77.8%, respectively in patients treated as 2nd or 3rd line, RR and DCR were 16.7% and 83.3%, respectively in patients treated as 4th or later line. Conclusion: Immune checkpoint inhibitors including nivolumab were considered more effective in the early phase on the theoretical basis, we observed patients with long PFS even in the late line usage. Therefore, indication of nivolumab should be considered as one of the promising treatment options even in the later line setting.
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Department of Biostatistics, Yokohama City University
Objective: Nivolumab (NIV) is a standard second-line treatment for previously treated patients with advanced non-small cell lung cancer (NSCLC). Although greater efficacy might be expected from a combination of NIV and a cytotoxic agent for advanced NSCLC, verification in a clinical trial is required. Since few reports on NIVþdocetaxel (DTX) combination therapy are available, we performed a feasibility study that examined the safety of this combination therapy prior to large-scale clinical trials. Methods: Eligibility criteria included a history of platinum-based chemotherapy, PS 0-1, and adequate organ function. Patients received NIV 3 mg/kg (days 1 and 15) and DTX 60mg/m2 (day 1) every 4 weeks for a maximum of 2 courses. The primary endpoints were safety of and dose-limiting toxicity (DLT) in the first course. This study used a 3 þ 3 design and was considered to be feasible if DLT occurred in one-third or less of the patients. The secondary endpoints were adverse events and a response rate. The DLT was defined in accordance with the phase Ib study by Kanda et al (Ann Oncol 2016) . Results: Between Aug 2016 and Sep 2016, three patients were enrolled in this trial at 2 centers in Japan. The first, second, and third study participants were: a 57-year-old woman with adenocarcinoma, a 44-year-old man with squamous cell carcinoma, a 58-year-old man with adenocarcinoma. Grade 3 or more adverse events occurred in only 1 patient(grade 4 neutropenia), and no DLT was observed in any patient. All patients completed 2 courses, with objective tumor responses of PD, SD and PR. Conclusion: NIVþ DTX combination therapy was safe, and further evaluation is warranted. Since combination NIV plus cytotoxic therapy has not been approved, we (Thoracic Oncology Research Group [TORG] ) are planning a phase II/III trial that compares NIVþ DTX with NIV alone for previously treated patients with advanced NSCLC, using an Advanced Medical Healthcare in Japan.
